Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased ...

Roughly one in five patients ditched survodutide due to adverse events ...

The results of two phase 3 trials investigating Survodutide, a weight loss drug from Boehringer Ingelheim, suggest that the ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...

Compared with nonusers, those on a GLP-1 receptor agonist had fewer thromboembolic events and higher survival.

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by ...

GoodRx reports that GLP-1 medications, while not FDA-approved for high blood pressure, can aid in lowering it through weight ...

Biomed Industries Presents Global Phase 3 Programs of NA-931 as Monotherapy and in Combination With Oral Semaglutide ...

Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain.

Over the past few years, GLP-1 drugs have transformed the treatment landscape for obesity and type 2 diabetes. By mimicking a ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...

This activity was supported by contracts between the National Academy of Sciences and American Academy of Neurology; American Brain Coalition; American College of Neuropsychopharmacology; American ...